Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
CNBC Stocks· Aug 5, 2026 · 7:06 AM
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 6 hours ago
Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
Investing.com
stocksabout 6 hours ago
Morgan Stanley private credit fund redemption requests remain elevated in third quarter
Investing.com
stocksabout 6 hours ago
Gemini hacked three companies in first known breakout by Google’s AI
Investing.com